Anaïs F. M. Noisier

Anaïs F. M. Noisier

Auto-generated profile, based on publicly available information

Anaïs F. M. Noisier

Medicinal Chemistry CVRM, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183 Mölndal, Sweden

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ANAnaïs F. M. Noisier
Anaïs F. M. Noisier
JSJenny Sandmark
Jenny Sandmark
FEFredrik Edfeldt
Fredrik Edfeldt
ABAnna Backmark
Anna Backmark
JBJohan Broddefalk
Johan Broddefalk
MLMalin Lemurell
Malin Lemurell
The GDF15–GFRaL–RET signaling complex is involved in a broad range of disease states, with agonistic action of GDF15 affecting metabolism and body weight control, while inhibition is indicated in cancer and wasting disorders like cachexia. Here, we describe the discovery of the peptide inhibitors of the GDF15–GFRaL protein–protein interaction to prevent RET-induced signaling using both a structure-guided design and a phage display approach. Phage display provided bicyclic peptide hits with high affinity for GFRaL, and these were dimerized to mimic the bidentate interaction of homodimeric GDF15. Guided by structural data, the monomeric peptides were converted into tandem Bicycle molecules with picomolar affinities, similar to that of the endogenous GDF15 ligand. These dimerized protein mimetics inhibited cell signaling in a functional assay and showed improved pharmacokinetic properties compared with their monomeric counterparts. This is the first example of a homodimeric Bicycle molecule inhibiting receptor complex formation, thereby antagonizing the intracellular signaling response.

5 July 2026 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
KPKevin Pinto-Gil
Kevin Pinto-Gil
LMLeonardo De Maria
Leonardo De Maria
ANAnaïs F. M. Noisier
Anaïs F. M. Noisier
SLSusan Leung
Susan Leung
AGArthur Garon
Arthur Garon
GGGian Marco Ghiandoni
Gian Marco Ghiandoni
The pharmaceutical industry’s shift toward new drug modalities, including therapeutic peptides, modified oligonucleotides, and antibody–drug conjugates, has exposed fundamental gaps in cheminformatics infrastructure. Unlike small molecules, which benefit from mature representation standards and reliable data exchange, new modalities lack robust and interoperable systems capable of capturing their structural and chemical complexity. Drawing on our experience at AstraZeneca, we examine these challenges across peptides, oligonucleotides, and ADCs, focusing on the limitations of current approaches, particularly HELM. We show that these limitations arise from both technical constraints, as new modalities exceed the scope of purely atomistic or sequence-based representations, and organizational gaps, including unresolved standardization and governance. We argue that local solutions exacerbate fragmentation, and that vendor- and community-driven standards, open implementations, and stronger governance are required to enable standardized and interoperable chemical information systems for next-generation therapeutics.

15 April 2026 in ChemRxiv
Verified
Preprint
Open access
ANAnaïs F M Noisier
Anaïs F M Noisier
GGGian Marco Ghiandoni
Gian Marco Ghiandoni
KPKevin Pinto-Gil
Kevin Pinto-Gil
AIAbdul Ingar
Abdul Ingar
JBJohan Broddefalk
Johan Broddefalk
LBLars Brive
Lars Brive
The growing interest in studying modified and cyclic peptides is constrained by limitations in how their chemical information is encoded, represented, and analysed. Traditional sequence formats such as FASTA only allow working with linear and natural peptides. HELM and BILN formats provide more versatile and extendible notation systems for the representation of peptides with non-natural monomers or cyclic arrangements. HELM is a notation that uses a database as a source of monomers where these are defined on their structure, identifier, and attachment points. While structural representations are canonicalized using established methods, there is currently no widely accepted convention for naming peptide monomers. In this manuscript, we develop on top of the guidelines proposed by Pistoia Alliance for the naming of non-natural amino acids for their representation using HELM. Our nomenclature extends on modifications of side chains and backbone, naming of homo amino acids and peptoids, and resolves ambiguous cases using a combination of systematic and pragmatic rules.